Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Mallinckrodt
Express Scripts
Merck
McKinsey

Last Updated: September 28, 2022

CLINICAL TRIALS PROFILE FOR LEUKINE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for LEUKINE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002594 ↗ Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors Completed National Cancer Institute (NCI) Phase 2 1994-09-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so that they stop growing or die. bone marrow transplantation and peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by bone marrow transplantation and/or peripheral stem cell transplantation in treating patients who have recurrent medulloblastoma or CNS germ cell tumors.
NCT00002594 ↗ Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors Completed Children's Oncology Group Phase 2 1994-09-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so that they stop growing or die. bone marrow transplantation and peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by bone marrow transplantation and/or peripheral stem cell transplantation in treating patients who have recurrent medulloblastoma or CNS germ cell tumors.
NCT00003093 ↗ Combination Chemotherapy in Treating Children With Neuroblastoma Completed National Cancer Institute (NCI) Phase 3 1988-03-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Combination chemotherapy plus surgery may be an effective treatment for neuroblastoma. PURPOSE: This phase III trial is studying how well combination chemotherapy followed by surgery works in treating young patients with neuroblastoma.
NCT00003093 ↗ Combination Chemotherapy in Treating Children With Neuroblastoma Completed Children's Oncology Group Phase 3 1988-03-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Combination chemotherapy plus surgery may be an effective treatment for neuroblastoma. PURPOSE: This phase III trial is studying how well combination chemotherapy followed by surgery works in treating young patients with neuroblastoma.
NCT00003199 ↗ Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer Completed National Cancer Institute (NCI) Phase 2 1997-11-01 This phase II trial studies how well giving combination chemotherapy and peripheral blood stem cell transplant followed by aldesleukin and sargramostim works in treating patients with inflammatory stage IIIB or metastatic stage IV breast cancer. Drugs used in chemotherapy, such as busulfan, melphalan, and thiotepa, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. A peripheral stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy. This may allow more chemotherapy to be given so that more tumor cells are killed. Aldesleukin may stimulate the white blood cells to kill breast cancer cells. Giving aldesleukin together with sargramostim may kill more tumor cells
NCT00003199 ↗ Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer Completed Fred Hutchinson Cancer Research Center Phase 2 1997-11-01 This phase II trial studies how well giving combination chemotherapy and peripheral blood stem cell transplant followed by aldesleukin and sargramostim works in treating patients with inflammatory stage IIIB or metastatic stage IV breast cancer. Drugs used in chemotherapy, such as busulfan, melphalan, and thiotepa, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. A peripheral stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy. This may allow more chemotherapy to be given so that more tumor cells are killed. Aldesleukin may stimulate the white blood cells to kill breast cancer cells. Giving aldesleukin together with sargramostim may kill more tumor cells
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for LEUKINE

Condition Name

Condition Name for LEUKINE
Intervention Trials
Lymphoma 7
Recurrent Neuroblastoma 6
Breast Cancer 6
Crohn Disease 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for LEUKINE
Intervention Trials
Leukemia 13
Neuroblastoma 13
Breast Neoplasms 11
Lymphoma 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for LEUKINE

Trials by Country

Trials by Country for LEUKINE
Location Trials
United States 633
Canada 61
Australia 48
United Kingdom 22
New Zealand 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for LEUKINE
Location Trials
Texas 38
California 30
New York 29
Pennsylvania 22
Ohio 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for LEUKINE

Clinical Trial Phase

Clinical Trial Phase for LEUKINE
Clinical Trial Phase Trials
Phase 4 4
Phase 3 11
Phase 2/Phase 3 1
[disabled in preview] 95
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for LEUKINE
Clinical Trial Phase Trials
Completed 55
Terminated 16
Recruiting 13
[disabled in preview] 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for LEUKINE

Sponsor Name

Sponsor Name for LEUKINE
Sponsor Trials
National Cancer Institute (NCI) 40
Bayer 14
M.D. Anderson Cancer Center 11
[disabled in preview] 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for LEUKINE
Sponsor Trials
Other 127
Industry 59
NIH 51
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Baxter
Medtronic
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.